WebOct 20, 2024 · Inhibitors targeting the epidermal growth factor receptor (EGFR) are an effective therapy for patients with non-small cell lung cancer harboring drug-sensitive activating mutations in the EGFR kinase domain. Drug resistance due to treatment-acquired mutations has motivated the development of successive generations of inhibitors that … WebView the profiles of people named Florian Wittke. Join Facebook to connect with Florian Wittke and others you may know. Facebook gives people the power...
Structural Basis for EGFR Mutant Inhibition by Trisubstituted
WebApr 23, 2024 · David E Heppner 1 2 , Marcel Günther 3 , Florian Wittlinger 3 , Stefan A Laufer 3 , Michael J Eck 1 2 Affiliations 1 Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States. WebSep 8, 2024 · Lazertinib (YH25448) is a novel third-generation tyrosine kinase inhibitor (TKI) developed as a treatment for EGFR mutant non-small cell lung cancer. To better understand lazertinib inhibition at the molecular level, we determined crystal structures of lazertinib in complex with both WT and mutant EGFR and compared its binding mode to that of … ct probate court schedule
Publications Heppner Lab - Buffalo
WebApr 23, 2024 · David E Heppner 1 2 , Marcel Günther 3 , Florian Wittlinger 3 , Stefan A Laufer 3 , Michael J Eck 1 2 Affiliations 1 Department of Cancer Biology, Dana-Farber … WebFeb 13, 2024 · The optimization of linkers that connect fragments within drug binding sites represents an impediment in fragment-based drug discovery (FBDD). To improve our understand of the molecular factors that enable effective fragment linking, we have produced a series of compounds that bind to the ATP and allosteric sites of the EGFR kinase … WebFeb 11, 2024 · Florian Wittlinger Michael J Eck Acquired drug resistance in epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer is a persistent challenge in cancer therapy. ctpr meaning